{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:04:46Z","timestamp":1789761886018,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K23360"],"award-info":[{"award-number":["24K23360"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019356","name":"SGH Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019356","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007369","name":"Fukuoka Public Health Promotion Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007369","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006724","name":"Japanese Urological Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006724","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.urolonc.2026.07.028","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:25:46Z","timestamp":1786969546000},"page":"598-606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravesical recurrence is associated with increased Treg and exhausted CD8+ T cells in upper tract urothelial carcinoma"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0949-2572","authenticated-orcid":false,"given":"Daisuke","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokiyoshi","family":"Tanegashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genshiro","family":"Fukuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Shiota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genki","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Itahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.07.028_bib0001","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.eururo.2025.02.023","article-title":"European Association of Urology guidelines on upper urinary tract urothelial carcinoma: summary of the 2025 update","volume":"87","author":"Masson-Lecomte","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0002","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.3390\/diagnostics14222491","article-title":"Multi-centre study of progression factors and intravesical recurrence in patients with urothelial carcinoma of the upper urinary tract","volume":"14","author":"Garc\u00eda-Morales","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0003","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2012.45.2128","article-title":"Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial","volume":"31","author":"Ito","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0004","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/JU.0000000000003480","article-title":"Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA\/SUO guideline","volume":"209","author":"Coleman","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0005","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.euros.2023.01.004","article-title":"Bladder recurrence following upper tract surgery for urothelial carcinoma: a contemporary review of risk factors and management strategies","volume":"49","author":"Mertens","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0006","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.urolonc.2014.04.006","article-title":"Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian upper tract collaboration","volume":"32","author":"Fradet","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0007","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1158\/1078-0432.CCR-05-0891","article-title":"Molecular evidence supporting field effect in urothelial carcinogenesis","volume":"11","author":"Jones","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0008","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/0140-6736(93)92066-3","article-title":"Metachronous multifocal development of urothelial cancers by intraluminal seeding","volume":"342","author":"Habuchi","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0009","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study","volume":"391","author":"Pag\u00e8s","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0010","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/JTO.0b013e3181d60fd7","article-title":"Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer","volume":"5","author":"Shimizu","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0011","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1158\/0008-5472.CAN-16-3167","article-title":"PD-1 status in CD8+ T cells associates with survival and Anti-PD-1 therapeutic outcomes in head and neck cancer","volume":"77","author":"Kansy","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2025.07.005","article-title":"Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer","volume":"43","author":"Ghisoni","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0013","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1158\/1078-0432.CCR-24-1561","article-title":"Efficacy, safety, and influence on the tumor microenvironment of neoadjuvant pembrolizumab plus ramucirumab for PD-L1-positive NSCLC: a phase II trial (EAST ENERGY)","volume":"30","author":"Aokage","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0014","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1078-0432.CCR-20-0197","article-title":"Recurrent HNSCC harbor an immunosuppressive tumor immune microenvironment suggesting successful tumor immune evasion","volume":"27","author":"Watermann","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0015","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0016","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41571-024-00870-6","article-title":"Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine","volume":"21","author":"Kumagai","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.11.041","article-title":"Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma","volume":"184","author":"Sun","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0018","doi-asserted-by":"crossref","DOI":"10.1172\/JCI180080","article-title":"Spatial and functional targeting of intratumoral Tregs reverses CD8+ T cell exhaustion and promotes cancer immunotherapy","volume":"134","author":"Zhou","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004605","article-title":"Tumor-associated tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells","volume":"10","author":"Noyes","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0020","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8\u207a tumor-reactive repertoire infiltrating human tumors","volume":"124","author":"Gros","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001823","article-title":"Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma","volume":"9","author":"Dai","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0022","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.1038\/s41467-024-53262-w","article-title":"Spatial dynamics of CD39+CD8+ exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer","volume":"15","author":"Tanoue","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0023","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41590-022-01210-5","article-title":"Autoreactive CD8+ T cells are restrained by an exhaustion-like program that is maintained by LAG3","volume":"23","author":"Grebinoski","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0024","doi-asserted-by":"crossref","first-page":"eadg1094","DOI":"10.1126\/sciimmunol.adg1094","article-title":"TIM-3+ CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies","volume":"9","author":"Minnie","year":"2024","journal-title":"Sci Immunol"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0025","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41419-025-07388-4","article-title":"TIGIT expression in extrahepatic cholangiocarcinoma and its impact on CD8+\u2009T cell exhaustion: implications for immunotherapy","volume":"16","author":"Tang","year":"2025","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0026","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0027","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00262-025-04024-0","article-title":"The effect of TIGIT and PD1 expression on T cell function and prognosis in adult patients with acute myeloid leukemia at diagnosis","volume":"74","author":"Xie","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0028","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.4049\/jimmunol.1401936","article-title":"PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells","volume":"194","author":"Park","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.urolonc.2026.07.028_bib0029","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1746573","article-title":"Heterogeneity of exhausted T cells in the tumor microenvironment is linked to patient survival following resection in hepatocellular carcinoma","volume":"9","author":"Liu","year":"2020","journal-title":"Oncoimmunology"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:12:40Z","timestamp":1789758760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926006216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1078143926006216"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.028","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravesical recurrence is associated with increased Treg and exhausted CD8+ T cells in upper tract urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}